A case of recalcitrant pediatric Vogt-Koyanagi-Harada disease successfully controlled with adalimumab.
A case of recalcitrant pediatric Vogt-Koyanagi-Harada disease successfully controlled with adalimumab.
J Formos Med Assoc. 2019 Jan 05;:
Authors: Su E, Oza VS, Latkany P
Abstract
Vogt-Koyanagi-Harada (VKH) disease is uncommon in the pediatric population and can have an aggressive course with serious visual sequelae. A 12-year-old Han Chinese American female, who presented with mild headaches and panuveitis with diffuse serous retinal detachments, was diagnosed with VKH. Despite treatment with a combination of high-dose systemic corticosteroids, intravitreal triamcinolone injection, and mycophenolate mofetil, ocular inflammation was inadequately controlled. Addition of adalimumab allowed for inflammation remission, improvement of vision, and tapering of systemic corticosteroids. Escalation of immunosuppression until remission appears to be critical in this population. Further research is needed to understand the complex pathophysiology of VKH and investigation for similar efficacy of other anti-tumor necrosis factor-alpha agents will need to be performed.
PMID: 30616991 [PubMed - as supplied by publisher]
Source: J Formos Med Assoc - Category: General Medicine Authors: Su E, Oza VS, Latkany P Tags: J Formos Med Assoc Source Type: research
More News: China Health | Corticosteroid Therapy | General Medicine | Headache | Humira | Pediatrics | Science | Triamcinolone | Vitamin A